Last Updated: November 16, 2026

Cytokinetics Company Profile

« Back to Dashboard


What is the competitive landscape for CYTOKINETICS

CYTOKINETICS has one approved drug.

There are two US patents protecting CYTOKINETICS drugs.

Summary for Cytokinetics
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Cytokinetics

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cytokinetics MYQORZO aficamten TABLET;ORAL 219083-003 Dec 19, 2025 RX Yes No 10,836,755 ⤷  Start Trial Y Y ⤷  Start Trial
Cytokinetics MYQORZO aficamten TABLET;ORAL 219083-001 Dec 19, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Cytokinetics MYQORZO aficamten TABLET;ORAL 219083-004 Dec 19, 2025 RX Yes No 10,836,755 ⤷  Start Trial Y Y ⤷  Start Trial
Cytokinetics MYQORZO aficamten TABLET;ORAL 219083-003 Dec 19, 2025 RX Yes No 12,370,179 ⤷  Start Trial ⤷  Start Trial
Cytokinetics MYQORZO aficamten TABLET;ORAL 219083-001 Dec 19, 2025 RX Yes Yes 10,836,755 ⤷  Start Trial Y Y ⤷  Start Trial
Cytokinetics MYQORZO aficamten TABLET;ORAL 219083-002 Dec 19, 2025 RX Yes No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Cytokinetics Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3740481 CA 2026 00034 Denmark ⤷  Start Trial PRODUCT NAME: AFICAMTEN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/25/2014 20260213
3740481 202640026 Slovenia ⤷  Start Trial PRODUCT NAME: AFICAMTEN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/25/2014; DATE OF NATIONAL AUTHORISATION: 20260212; AUTHORITY FOR NATIONAL AUTHORISATION: EU
3740481 301392 Netherlands ⤷  Start Trial PRODUCT NAME: AFICAMTEN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/25/2014 20260213
3740481 2026C/731 Belgium ⤷  Start Trial PRODUCT NAME: AFICAMTEN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/25/2014 20260213
3740481 LUC50059 Luxembourg ⤷  Start Trial PRODUCT NAME: AFICAMTEN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/25/2014 20260213
3740481 PA2026525 Lithuania ⤷  Start Trial PRODUCT NAME: AFIKAMTENAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/25/2014 20260212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.